(19)
(11) EP 4 522 123 A1

(12)

(43) Date of publication:
19.03.2025 Bulletin 2025/12

(21) Application number: 23803183.5

(22) Date of filing: 07.05.2023
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 47/10(2017.01)
A61K 31/4523(2006.01)
A61K 47/20(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/20; A61K 47/10; A61K 9/0053; A61K 47/32; A61K 31/4545
(86) International application number:
PCT/IN2023/050442
(87) International publication number:
WO 2023/218482 (16.11.2023 Gazette 2023/46)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 09.05.2022 IN 202221026671

(71) Applicant: SYRI Research Private Limited
Vadodara, Gujarat 391740 (IN)

(72) Inventors:
  • ACHLIYA, Girish Shantilal
    Vadodara, Gujarat 391740 (IN)
  • POPTANI, Sanjaykumar D
    Vadodara, Gujarat 391740 (IN)
  • BHAVSAR, Shreyaskumar Vikasbhai
    Vadodara, Gujarat 391740 (IN)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)

   


(54) LIQUID ORAL FORMULATION OF APIXABAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF